CL2025001234A1 - Compuestos heterocíclicos como antagonistas de sting - Google Patents

Compuestos heterocíclicos como antagonistas de sting

Info

Publication number
CL2025001234A1
CL2025001234A1 CL2025001234A CL2025001234A CL2025001234A1 CL 2025001234 A1 CL2025001234 A1 CL 2025001234A1 CL 2025001234 A CL2025001234 A CL 2025001234A CL 2025001234 A CL2025001234 A CL 2025001234A CL 2025001234 A1 CL2025001234 A1 CL 2025001234A1
Authority
CL
Chile
Prior art keywords
disease
syndrome
heart failure
sting
interferonopathies
Prior art date
Application number
CL2025001234A
Other languages
English (en)
Inventor
Mayer Camilla
Dahmann Georg
Ruth Handschuh Sandra
Nar Herbert
Oost Thorsten
Gross Patrick
Hoffmann Matthias
Brambilla Marta
Li Jun
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2025001234A1 publication Critical patent/CL2025001234A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona a compuestos de fórmula 1; y su uso como antagonistas de STING, por ejemplo para el tratamiento de una enfermedad que se selecciona entre el grupo que consiste en: lupus eritematoso sistémico (SLE), interferonopatías (monogénicas y digénicas) (incluyendo a la vasculopatía asociada a STING con inicio en la infancia (SAVI), síndrome de Aicardi-Goutières (AGS), síndrome COPA, y perniosis lúpica familiar), interferonopatías de tipo 1 con mutaciones en los genes DNASE2 o ATAD3A, degeneración macular relacionada con la edad (AMD), retinopatía, glaucoma, esclerosis lateral amiotrófica (ALS), diabetes, obesidad, enfermedad inflamatoria intestinal (IBD), enfermedad pulmonar obstructiva crónica (EPOC), síndrome de Bloom, síndrome de Sjogren, enfermedad de Parkinson, insuficiencia cardíaca y cáncer, esclerosis sistémica (SSc), dermatomiositis, enfermedad del hígado graso no alcohólico (NAFLD), esteatohepatitis no alcohólica (NASH), insuficiencia hepática aguda o crónica (ACLF), enfermedad pulmonar intersticial (ILD), fibrosis pulmonar idiopática (IPF), envejecimiento/trastornos musculares, septicemia, insuficiencia cardíaca, artritis reumatoide y osteoartritis.
CL2025001234A 2022-10-28 2025-04-24 Compuestos heterocíclicos como antagonistas de sting CL2025001234A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263381349P 2022-10-28 2022-10-28
EP22210157 2022-11-29

Publications (1)

Publication Number Publication Date
CL2025001234A1 true CL2025001234A1 (es) 2025-08-29

Family

ID=88600218

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2025001234A CL2025001234A1 (es) 2022-10-28 2025-04-24 Compuestos heterocíclicos como antagonistas de sting

Country Status (16)

Country Link
EP (1) EP4608830A1 (es)
JP (1) JP2026510538A (es)
KR (1) KR20250096817A (es)
CN (1) CN119998286A (es)
AU (1) AU2023368953A1 (es)
CA (1) CA3269346A1 (es)
CL (1) CL2025001234A1 (es)
CO (1) CO2025003882A2 (es)
CR (1) CR20250111A (es)
DO (1) DOP2025000092A (es)
IL (1) IL319947A (es)
JO (1) JOP20250093A1 (es)
MX (1) MX2025004817A (es)
PE (1) PE20251576A1 (es)
TW (1) TW202434213A (es)
WO (1) WO2024089155A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025228900A1 (en) * 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Arylamide substituted indazoles and the use thereof as medicament

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103214484B (zh) * 2005-12-13 2016-07-06 因塞特控股公司 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶
US20130059866A1 (en) 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
WO2019069270A1 (en) 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited GENERATOR STIMULATOR MODULATORS (STING) INTERFERON
WO2019122202A1 (en) 2017-12-20 2019-06-27 Ecole Polytechnique Federale De Lausanne (Epfl) Sting inhibitors
EP4155293B1 (en) * 2018-06-07 2025-07-30 The Regents of The University of Michigan Prc1 inhibitors and methods of treatment therewith
WO2021138419A1 (en) * 2019-12-31 2021-07-08 Ifm Due, Inc, Compounds and compositions for treating conditions associated with sting activity
US12065427B2 (en) * 2021-04-29 2024-08-20 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating STING

Also Published As

Publication number Publication date
EP4608830A1 (en) 2025-09-03
MX2025004817A (es) 2025-06-02
JP2026510538A (ja) 2026-04-08
CA3269346A1 (en) 2024-05-02
CR20250111A (es) 2025-05-05
CO2025003882A2 (es) 2025-05-08
PE20251576A1 (es) 2025-06-12
CN119998286A (zh) 2025-05-13
AU2023368953A1 (en) 2025-03-27
JOP20250093A1 (ar) 2025-04-27
DOP2025000092A (es) 2025-05-15
IL319947A (en) 2025-05-01
TW202434213A (zh) 2024-09-01
WO2024089155A1 (en) 2024-05-02
KR20250096817A (ko) 2025-06-27

Similar Documents

Publication Publication Date Title
DOP2025000092A (es) Compuestos heterocíclicos como antagonistas de sting
ES2890981T3 (es) Compuestos de modulación de FXR (NR1H4)
ES2973500T3 (es) Compuesto de isoxazol como agonista de FXR y composiciones farmacéuticas que lo comprenden
CO2021008089A2 (es) Agonistas de glp-1r y usos de los mismos
US10988467B2 (en) Compounds as ROR gamma modulators
DOP2022000126A (es) Derivados de furoindazol
HRP20210252T1 (hr) Heterociklički amidi kao inhibitori kinaze
US12091392B2 (en) Compounds, compositions and methods
CN107073130A (zh) 脂肪酸及其在与生物分子缀合中的用途
MA33818B1 (fr) Nouveaux antagonistes du récepteur ccr2 et leurs utilisations
AR103954A1 (es) Análogos de amilina
PH12019550226A1 (en) Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
BRPI0509341A (pt) anatagonistas de cgrp hetorocìclicos para o tratamento de enxaqueca
ATE501151T1 (de) Substituierte pyrano ä2, 3 - büpyridinderivate als cannabinoid-1 rezeptormodulatoren
TW200621724A (en) Sulfonyl benzimidazole derivatives
EA202092678A1 (ru) 1,3-тиазол-2-ил-замещенные бензамиды для лечения заболеваний, ассоциированных с сенситизацией нервных волокон
RU2015137976A (ru) Ингибиторы лейкотриен а4-гидролазы
CN112839940A (zh) 胺基脲敏感性胺氧化酶抑制剂制备及其应用
US20250026739A1 (en) Compounds and radioligands for targeting neurotensin receptor and uses thereof
JP2013526554A5 (es)
US9902715B2 (en) Compounds
AR132060A1 (es) Compuestos heterocíclicos como antagonistas de sting
AR124395A1 (es) Agonistas del receptor del polipéptido tipo glucagón 1 (glp-1) de acción prolongada y métodos de uso de los mismos
DE602006019213D1 (de) Benzimidazolonderivate als cb2-rezeptor-liganden
WO2020037350A1 (en) Adamantanyl-substituted benzamide compounds and their use as p2x7 receptor antagonists